CBD oil is made by extracting CBD from the cannabis plant, then diluting CBD oil has even been used to safely treat insomnia and anxiety in. The use of CBD oil might complement a medical approach to treating physical and mental diseases. It is worth discussing with your. Cannabidiol comes from the cannabis plant, and has a wealth of health benefits. tongue), as are capsules, creams that can be applied topically, and e-liquid for vape pens. CBD oil could be beneficial in epilepsy treatment.
Treat? To Can What Be Used CBD
Depression has been found to occur in children at an incidence rate of 0. In prepubertal children, depression occurs in boys and girls at an equal rate. Generally, depression in men and women has the highest rates in those aged between 25 to 44 years and the incidence of severe depression increases with age.
There is a wide range of treatments for depression which have proven effective in improving symptoms. A combination of medications and psychotherapy is effective in reducing the symptoms of depression, and therapy with either form alone is often ineffective. Combination therapy has been found to increase quality of life and improve treatment compliance in patients with depression.
Advanced treatment techniques used for the treatment of depression include electroconvulsive therapy which uses high-energy electric stimulation, and bright-light therapy involving exposure of an individual with depression to bright light at an intensity of 10, lux for a period of one hour in the morning.
Psychotherapy is often combined with medications in the treatment of depression. There are different types of therapy for depression and these can be grouped based on their efficacies. Examples of efficacious and specific therapies include cognitive behavioral therapy, problem-solving therapy, and interpersonal therapy which help the individual modify their behaviors and interpersonal relationships.
An example of an efficacious therapy includes mindfulness-based cognitive therapy to prevent a recurrence or relapse, and an example of possibly efficacious therapy is continuation cognitive therapy to prevent recurrence by helping the individual develop positive thinking and behavioral patterns.
Medications used for treating depression are of different classes, each with a different mechanism of action, characteristics, and side effects. These drugs generally increase the concentration of stimulant substances in the brain to improve the depressive symptoms. Patients with depression could benefit from a number of home remedies which could help to improve their symptoms, in addition to antidepressants and therapy:.
Cannabidiol CBD is a naturally occurring chemical compound found in the hemp plant. It is one of the numerous unique compounds called cannabinoids which naturally occur in hemp. Generally, cannabinoids can be produced in the body these are known as endocannabinoids or found in the hemp plant as phytocannabinoids.
CBD is a phytocannabinoid which helps to stimulate the regulation of the central nervous system. CBD, therefore, helps supplement the effects of endocannabinoids in regulating appetite, mood, functions of the immune system, sensation, and keeping our bodies working normally.
CBD oil is made from hemp plants and can be purchased legally in the United States. CBD is available in different forms such as tinctures, concentrates, capsules, sprays, tapes, and topicals. Both of them represent the commonest compounds found in the plant. However, they have numerous differences. Financial Assistance for Dementia Care.
CBD is derived from Cannabis plants, similar to how caffeine is derived from the coffee bean, or aspirin from the bark of a Willow tree. CBD oil is the most common form of administration of the compound with the oil contained in a gel cap or dropper bottle. The dementia related conditions that can be helped by CBD include: There are three ways which CBD can work to improve health outcomes for persons with dementia; by reducing inflammation, by reducing oxygen build up and by working as a brain stimulant and neuroprotectant.
In recent studies, CBD has been shown to reduce or remove the impact of inflammation, oxygen build up and brain cell decline. When inflammation happens in the brain, oxygen is released as a result. The greater the inflammation, the greater the negative impact.
Memory loss and other brain deterioration indirectly leads to increased oxygen in the brain. CBD is an antioxidant, which helps reduce the problems associated with oxygen stress. Brain functions negatively impacted by oxygen stress can be improved by using CBD. The potential of stimulating brain tissue was recently discovered as a potential benefit of CBD. A study by Australian researchers Tim Karl and Carl Group found that CBD promotes the growth and development of brain cells, which were shown to reduce the decline of memory and other brain functions.
To effectively treat vascular dementia, a study by the US National Institute of Health NIH found that activating CB2 cannabinoid receptors in the brain helped recover better blood flow to the brain. Activating the CB2 receptors with CBD has increased brain cell activity and helped reduce brain cell damage commonly associated with vascular dementia.
Lewy body dementia LBD is a disease associated with abnormal deposits of a protein called alpha-synuclein in the brain. These deposits, called Lewy bodies, affect chemicals in the brain whose changes, in turn, can lead to problems with thinking, sleeping, movement, behavior, and mood.
Unlike most pain, anxiety or behavior management drugs, CBD does not block acetylcholine, the main chemical that LBD attacks. Research has shown that CBD can be an effective anti-inflammatory agent, reduce motor symptoms tremor, rigidity, bradykinesia and maintain circadian sleep rhythms.
Unlike most anti-psychotic drugs, CBD does not lead to an increased risk of death. Marijuana was suggested as treatment of muscle spasticity as early as the s. Responses varied, but benefit was seen in patients with tonic spasms. Improved motor coordination was seen when patients with MS, seriously disabled with tremor and ataxia, were given oral THC. MS is not the only disease state where the neuroprotective potential of cannabinoids can be seen.
In animal experiments, 2 weeks after the application of 6-hydroxydopamine, a significant depletion of dopamine contents and a reduction in tyrosine hydroxylase activity in the lesioned striatum were noted, and were accompanied by a reduction in tyrosine hydroxylase-messenger ribonucleic acid mRNA levels in the substantia nigra.
Daily administration of THC over 2 weeks produced a significant irreversible waning in the magnitude of these changes, which may be relevant in the treatment of Parkinson's disease see below The cannabinoids have a neuroprotective activity not only in vitro but also in vivo: HU, a potent synthetic analog of THC, increases survival of mouse cerebellar granule cells exposed to 6-hydroxydopamine.
Rimonabant exerted neuroprotection independently of its cannabinoid receptor-blocking effect. A trend toward faster and better neurologic outcome was also observed. Atherosclerosis is a chronic inflammatory disease, and is the primary cause of heart disease and stroke in Western countries.
Oral treatment with a low dose of THC inhibits atherosclerosis progression in an apolipoprotein E knockout mouse model, through pleiotropic immunomodulatory effects on lymphoid and myeloid cells. Thus, THC may be a valuable target for treating atherosclerosis. Its concentrations are significantly increased in three different inflammatory and neuropathic conditions. The enhanced levels may possibly be related to a protective local anti-inflammatory and analgesic action. In experiments with obese vs lean rats, rimonabant was found to be a potent inhibitor of sensory hypersensitivity associated with CFA-induced arthritis in obese rats, in which the inflammatory reaction is more severe than in lean rats.
It may thus have therapeutic potential in obesity-associated inflammatory diseases. Parkinson's disease PD is a chronic, progressive neurodegenerative disorder. The main pathological feature of PD is the degeneration of dopamine DA -containing neurons of the substantia nigra, which leads to severe DAergic denervation of the striatum. The irreversible loss of the DA-mediated control of striatal function leads to the typical motor symptoms observed in PD, ie, bradykinesia, tremor, and rigidity.
It has been proposed that cannabinoids may have some beneficial effects in the treatment of PD. The majority of PD patients undergoing levodopa therapy develop disabling motor complications dyskinesias within 10 years of treatment.
Recent studies in animal models and in the clinic suggest that CB1 receptor antagonists could prove useful in the treatment of both parkinsonian symptoms and levodopa-induced dyskinesia, whereas CB1 receptor agonists could have value in reducing levodopa-induced dyskinesia. This effect was significantly reduced by coinjection with the cannabinoid receptor agonist WIN 55, The simultaneous administration of the CB1 antagonist rimonabant with quinpirole and WIN 55, blocked the effect of WIN 55, on quinpirole-induced alleviation of akinesia.
This effect was also reversed by rimonabant. The injection of 0. In clinical trials, the cannabinoid receptor agonist nabilone significantly reduced levodopainduced dyskinesia in PD. Advanced grades of HD showed an almost total loss of CB1 receptors and a further depletion of Dl receptors in the caudate nucleus, putamen, and globus pallidus internus, and an increase in GABA A receptor binding in the globus pallidus internus.
Indeed, arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of HD generated by bilateral intrastriatal application of 3-nitropropionic acid 3-NP. However, both capsaicin VR1 agonist and CP55, an CB1 agonist had antihyperkinetic activity Quinolinic acid QA is an excitotoxin which, when injected into the rat striatum, reproduces many features of HD by stimulating glutamate outflow.
Perfusion with WIN 55, significantly and dose-dependently prevented the increase in extracellular glutamate induced by QA. Thus, the stimulation of CB1 receptors might lead to neuroprotective effects against excitotoxic striatal toxicity.
Tourette syndrome TS is a complex inherited disorder of unknown etiology, characterized by multiple motor and vocal tics. Anecdotal reports have suggested that the use of cannabis might improve tics and behavioral problems in patients with TS.
There was a significant improvement of motor tics, vocal tics and obsessive-compulsive behavior after treatment with THC. Amyotrophic lateral sclerosis ALS is a fatal neurodegenerative disorder characterized by a selective loss of motor neurons in the spinal cord, brain stem, and motor cortex.
Many effects of marijuana may be applicable to the management of ALS. These include analgesia, muscle relaxation, bronchodilation, saliva reduction, appetite stimulation, and sleep induction. In addition, its strong antioxidative and neuroprotective effects may prolong neuronal cell survival. Furthermore, genetic ablation of the FAAH enzyme, which results in raised levels of the endocannabinoid anandamide, prevented the appearance of disease signs in these mice.
Ablation of the CB1 receptor, in contrast, had no effect on disease onset in these mice, but significantly extended life span. Together these results show that cannabinoids have significant neuroprotective effects in this model of ALS, and suggest that these beneficial effects may be mediated by nonCB1 receptor mechanisms. Administration at the onset of tremors delayed motor impairment in treated mice when compared with vehicle controls ; moreover, AM prolonged survival in these mice.
Studies on cannabinoid anticonvulsant activity began in , when CBD, and four CBD derivatives, CBD-aldehyde-diacetate, 6-oxo-CBD-diacetate, 6-hydroxy-CBD-tri-acetate and 9-hydroxy-CBD-triacetate were shown to protect against maximal electroshock convulsions in mice, to potentiate pentobarbital sleeping-time and to reduce spontaneous motor activity.
Furthermore, it appears that CBD enhances the anticonvulsant effects of drugs in major seizures and reduces their effects in minor seizures. The induction of status epilepticus-like activity by CB1 receptor antagonists was reversible and could be overcome by maximal concentrations of CB1 agonists. Cannabis use is common in patients with bipolar disorder, and anecdotal reports suggest that some patients use marijuana to alleviate symptoms of both mania and depression.
The effect of cannabinoids on schizophrenia is controversial. Neuropsychological results in THC-intoxicated normal volunteers exhibit strong similarities with data acquired from patients suffering from productive schizophrenic psychoses, as regards disturbances in internal regulation of perceptual processes.
Data from experimental-psychological tests show that personality changes generated by schizophrenia progression are comparable to psychopathological phenomenon due to cannabis intoxication. This argues against a distinct schizophrenia-like psychosis caused by cannabis. The group receiving the CB1 antagonist did not differ from the group receiving placebo on any outcome measure. CBD causes antipsychotic effects. Posttraumatic stress disorder PTSD is a term for severe psychological consequences of exposure to, or confrontation with, stressful, highly traumatic events.
Cannabinoids are believed to help in such cases. AMtreated animals showed decreased shock-induced reinstatement of fear. SRI blocked the effects of OL, suggesting that endogenous anandamide plays a facilitator role in extinction through a CB1 receptor mechanism of action. However, upon repeated stress or acute severe stress, CB1 receptor deficiency causes persistent behavioral inhibition. Repeated bell stress seemed to cause a cumulative fear in CB1 receptor knockout mice. CB1 receptor gene polymorphism is known to modify transcription of the gene.
In patients with Parkinson's disease, the presence of two long alleles, with more than 16 repeated AAT trinucleotides in the CNR1 gene, was associated with a reduced prevalence of depression. CBD, and some derivatives, were found to cause a selective anxiolytic effect in the elevated plus-maze, within a limited range of doses. The effects of marijuana on human sleep patterns were noticed long ago. Asthma is a chronic disease of the respiratory system in which the airway occasionally constricts, becomes inflamed, and is lined with excessive amounts of mucus.
In animal experiments, after methacholine-induced or exercise-induced bronchospasm, marijuana caused a prompt improvement of the bronchospasm and associated hyperinflation.
The daily use of THC was not associated with clinical tolerance. Maximal bronchodilatation was achieved more rapidly with salbutamol, but at 1 hour both drugs were equally effective. No cardiovascular or mood disturbance was detected, and plasma total cannabinoids at 15 minutes were not detected by radioimmunoassay. The mode of action of THC differed from that of sympathomimetic drugs. In another study, THC induced sympathetic stimulation and parasympathetic inhibition of cardiovascular control pathways.
The peak heart rate rise after THC was attenuated by atropine and by propranolol, and nearly abolished by atropine-propranolol pretreatment. With repetitive dosing supine bradycardia and decreased blood pressure with tolerance to orthostatic hypotension were observed. A number of studies suggest that there is a correlative, but not necessarily causal, relationship between glaucoma and systemic hypertension.
Ocular hypertension OHT refers to any situation in which intraocular pressure is higher than normal, and is the most important risk factor for glaucoma. In contrast, noladin ether decreased IOP immediately after topical administration, and no initial IOP increase was observed. CB2 mRNA was undetectable. Ocular toxicity was seen after THC treatment, consisting of conjunctival erythema and chemosis as well as corneal opacification. Although these changes also occurred with marijuana extract, their intensity was much reduced.
In contrast, no ocular toxicity was apparent during administration of plant cannabinoids other than THC.
The results indicate that THC may have value as a hypotonizing ocular drug. The intensity and duration of the arterial and ocular pressure responses to THC were greater in hypertensives than in normotensive patients; the changes in ocular pressure paralleled the changes in blood pressure in glaucoma patients.
The antiproliferative action of cannabinoids on cancer cells was first noticed in the s. Since then cannabinoids were found to act on various cancer cell lines, through various mechanisms.
Moreover, cannabinoid challenge decreased the efficiency of glioma stem-like cells to initiate glioma formation in vivo. Activation of these receptors decreased growth, proliferation, angiogenesis, and metastasis, and increased apoptosis, of melanomas in mice. These effects were prevented by blockade of the CB2 cannabinoid receptor or by pharmacologic inhibition of ceramide synthesis de novo.
THC inhibited tumor-cell proliferation in vitro, decreased tumor-cell Ki67 immunostaining and prolonged the survival time of two of the patients. Many drugs used today can cause addiction and are misused and abused, for example opiates, cocaine, benzodiazepines, barbiturates, cholinergic agonists, ketamine, , dopaminergic agonists, amphetamines, and others.
Nevertheless they are still an important part of our pharmacopeia. Marijuana was used for centuries as a medicinal plant, but during the last century, because of its abuse and addictive potential it was taken out of clinical practice. Now, we believe that its constituents and related compounds should be brought back to clinical use. The endocannabinoid system is a very complex one and regulates numerous processes, in parallel with other wellknown systems, such as the adrenergic, cholinergic, and dopaminergic systems.
National Center for Biotechnology Information , U. Journal List Dialogues Clin Neurosci v. Kogan , MSc Natalya M. Author information Copyright and License information Disclaimer. This is an open-access article distributed under the terms of the Creative Commons Attribution License http: This article has been cited by other articles in PMC.
Abstract Cannabis sativa L. Abstract Las preparaciones de Cannabis sativa L. Addiction to canabis, and the influence of cannabis on addiction to other substances Marijuana may produce mild dependence in humans. Negative effects of cannabis other than addiction There are some negative effects of cannabis use other than addiction, most of them related to alterations of attentional and cognitive functions or other neuropsychological and behavioral effects.
Therapeutic uses of cannabinoids Obesity, anorexia, emesis Cannabis has been known for centuries to increase appetite and food consumption. Pain Cannabis has been used for millennia as a pain-relieving substance. Multiple sclerosis, neuroprotection, inflammation Inflammation, autoimmune response, demyelination, and axonal damage are thought to participate in the pathogenesis of MS. Parkinson's disease, Huntington's disease, Tourette's syndrome, Alzheimer's disease, epilepsy Parkinson's disease PD is a chronic, progressive neurodegenerative disorder.
Bipolar disorder, schizophrenia, post-traumatic stress disorder PTSD , depression, anxiety, insomnia Cannabis use is common in patients with bipolar disorder, and anecdotal reports suggest that some patients use marijuana to alleviate symptoms of both mania and depression.
Asthma, cardiovascular disorders, glaucoma Asthma is a chronic disease of the respiratory system in which the airway occasionally constricts, becomes inflamed, and is lined with excessive amounts of mucus. Cancer The antiproliferative action of cannabinoids on cancer cells was first noticed in the s.
Conclusion Many drugs used today can cause addiction and are misused and abused, for example opiates, cocaine, benzodiazepines, barbiturates, cholinergic agonists, ketamine, , dopaminergic agonists, amphetamines, and others.
Early medical use of cannabis. Untersuchung der Cannabis sativa. Repertorium fur die Pharmacie. Note sur le haschisch. A historical overview of chemical research on cannabinoids. Isolation, structure and partial synthesis of the active constituent of hashish.
J Am Chem Soc. Marihuana, an annotated bibliography. Withdrawal symptoms in cannabis indica addicts. The addictive potential of cannabis. Clinical studies of cannabis tolerance and dependence. Ann N Y Acad Sci. Treatment of cannabis use disorders: Cannabis addiction and Telic Dominance Scale. Clinical trial of abstinencebased vouchers and cognitive-behavioral therapy for cannabis dependence. J Consult Clin Psychol. Addictive potential of cannabinoids: Failure of Delta 9 -tetrahydrocannabinol and CP 55, to maintain intravenous self-administration under a fixed-interval schedule in rhesus monkeys.
Endocannabinoid system and alcohol addiction: Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. SR, a central cannabinoid CB 1 receptor antagonist, blocks the motivational and dopaminereleasing effects of nicotine in rats. The diagnosis of alcohol and cannabis dependence addiction in cocaine dependence addiction.
Behavioral effects of cocaine alone and in combination with ethanol or marijuana in humans. Marihuana smoking increases plasma cocaine levels and subjective reports of euphoria in male volunteers. Involvement of cannabinoid CB1 receptors in drug addiction: Rimonabant, a CB1 antagonist, blocks nicotineconditioned place preferences.
Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: The role of the cannabinoid system in nicotine addiction. Successful control of lipids, kilos and cigarettes]. Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs. Expert Opin Investig Drugs. Adenosine A2a blockade prevents synergy between mu-opiate and cannabinoid CB1 receptors and eliminates heroin-seeking behavior in addicted rats.
Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: Cell Mol Life Sci. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther. Cognitive functioning of longterm heavy cannabis users seeking treatment.
Chronic cognitive impairment in users of 'ecstasy' and cannabis. Cannabis use, cognitive performance and mood in a sample of workers. Long-term effects of frequent cannabis use on working memory and attention:
Everything you need to know about CBD oil
Advanced treatment techniques used for the treatment of depression include CBD oil is made from hemp plants and can be purchased legally in the United. People use it to get relief from their symptoms, not to try to get high. The experts also say that CBD might be able to treat epilepsy (where. Only one purported use for cannabidiol, to treat epilepsy, has significant There also is some indication that CBD might harm the liver.